Breakpoints29 Mar 2024

#95 – A to Z on R&D: Challenges and Solutions for Sustained Antimicrobial Drug Development

In this episode, Drs. Helen Boucher (@hboucher3), Ramy Elshaboury, and Mike Dudley (@MikeMNDudley) join host, Megan Klatt (@MeganKlatt3), to discuss barriers to antimicrobial drug development, potential incentives and legislation to promote market growth, and what we can do to ensure the antimicrobial pipeline doesn’t run dry.

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp

References

An analysis of antibacterial drug development trends in the United States, 1980-2019: Dheman N, et al. Clin Infect Dis. 2021 Dec 6;73(11):e4444-e4450. doi:10.1093/cid/ciaa859. PMID: 32584952.
Antibacterial R&D at a crossroads: we’ve pushed as hard as we can…now we need to start pulling!: Rex JH, Outterson K. Clin Infect Dis. 2021 Dec 6;73(11):e4451-4453. doi:10.1093/cid/ciaa852. PMID: 32584949.
No Patient Left Behind (website): https://www.nopatientleftbehind.org/ (many useful explainers of how the investment, innovation cycle, and drug pricing work)
ISPOR special task force report on defining elements of value in health care – a health economics approach: Lakdawalla DN, et al. Value Health. 2018 2018 Feb;21(2):131-139. doi: 10.1016/j.jval.2017.12.007. PMID: 29477390.
Generalized cost-effectiveness analysis to assess treatment value in hepatitis C: Chou JW, et al. Am J Manag Care. 2023 Dec;29(12):696-703. doi: 10.37765/ajmc.2023.89468. PMID: 38170486.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(134)

#134 – ESCMID Global Trials: PETER PEN and ASTARTE

Professor Mical Paul and Professor Jesús Rodríguez-Baño join Professor Josh Davis and Dr Erin McCreary for a special Breakpoints and Communicable podcast collaboration. This episode discusses the ‘Tri...

8 Mai 1h 3min

#133 – Trash talk: Earth Day Special on Healthcare Sustainability and Stewardship

Climate change in the context of healthcare can feel overwhelming but it doesn’t have to be paralyzing. We’re diving into the intersection of climate change and antimicrobial resistance with a focus o...

17 Apr 48min

#132 – Complicated UTIs: What’s Crystal Clear & What’s Still Cloudy

Episode Notes Complicated UTIs just got a whole lot less complicated—or did they? Dr. Dana Bowers and Kyle Molina (@kcmolinaID) join Dr. Whitney Buckel to break down what’s new, what’s controversial, ...

13 Mar 1h 8min

#131 – Drawing the Line: The Writing, Reach, and Limits of Guidelines

In this third collaboration between SIDP’s Breakpoints and ESCMID’s Communicable podcasts, hosts Erin McCreary and Angela Huttner invite two veteran authors of guidelines and guidances, Pranita Tamma ...

22 Feb 1h

#130 – Dosing Consult: Amoxicillin

Drs. Ted Morton and Christine Lockowitz join Dr. Ryan Moenster to discuss all things amoxicillin, particularly in our pediatric patients. Our guests answer common questions, such as, what formulations...

30 Jan 1h

#129 – Game of Spores: Blasto, Histo, Crypto, and Cocci

We’re starting 2026 off with a BLAST as Dr. Gregory Eschenauer and Dr. George R Thompson make their Breakpoints debut to discuss Blastomyces, Histoplasma, Coccidioides, and Cryptococcus. They join hos...

16 Jan 1h 22min

#128 – IDWeek 2025 Recap

Ring in the end of the year with our Breakpoints hosts and a review of all things IDWeek 2025! Join Drs. Erin McCreary, Julie Ann Justo, Whitney Buckel, and Ryan Moenster as they cover top late breaki...

19 Des 20251h 35min

#127 – What’s Pneu in Community-Acquired Pneumonia Part 2

As promised, our host Dr, Ryan Moenster is back and breaking down the recently published ATS pneumonia guidelines — what’s pneu, what’s controversial, and what it means for your antimicrobial game! Dr...

28 Nov 202552min